Lanreotidă Zentiva

Lanreotide, the active ingredient in Lanreotidă Zentiva, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed to manage hormone‑related disorders such as acromegaly and certain neuroendocrine tumors in adult patients. GNH USA supplies Lanreotidă Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lanreotidă Zentiva is a somatostatin analogue used in endocrine‑related disease pathways. - Acromegaly: reduces excess growth hormone secretion and helps normalize IGF‑1 levels. - Neuroendocrine tumors (carcinoid syndrome): controls hormone‑driven flushing and diarrhea. - Hormone‑secreting tumors: mitigates hypersecretion of various hormones, improving clinical symptoms.

Lanreotidă Zentiva may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Nausea: transient feeling of queasiness. - Diarrhea: loose stools that may be mild to moderate. - Headache: occasional throbbing pain. - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.

Serious or Rare Side Effects: - Gallbladder disease: formation of gallstones or cholecystitis. - Pancreatitis: inflammation of the pancreas requiring medical attention. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms that may need monitoring.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications. - Glucose monitoring: check blood sugar regularly, especially in diabetic patients. - Gallbladder evaluation: assess for gallstones or biliary disease prior to treatment. - Cardiac assessment: review history of arrhythmias or conduction disorders. - Concomitant hormone therapies: adjust doses of insulin or oral hypoglycemics as needed. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Other somatostatin analogues: additive hormonal suppression may increase adverse effects. - Insulin or oral hypoglycemics: heightened risk of hypoglycemia, requiring dose adjustment. - QT‑prolonging agents: potential for serious cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - CYP450 substrates: lanreotide may alter metabolism of certain drugs, affecting their plasma levels. - Antiplatelet or anticoagulant drugs: increased bleeding tendency may occur. - Diuretics: electrolyte imbalances could be exacerbated, necessitating periodic labs.